European Union - Estonian - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

European Union - Estonian - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kiiresti arenev raske relapsing remitting sclerosis multiplex määratud 2 või enam puuet ägenemiste ühe aasta, ja on 1 või enam gadoliinium suurendada kahjustused aju mri või olulist kasvu, t2 kahjustus koormus võrreldes varasema hiljutise mrt.

European Union - Estonian - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Estonia - Estonian - Ravimiamet

mylan pharmaceuticals limited - alendroonhape+kolekaltsiferool - tablett - 70mg+2800rÜ 12tk; 70mg+2800rÜ 4tk

Estonia - Estonian - Ravimiamet

mylan pharmaceuticals limited - alendroonhape+kolekaltsiferool - tablett - 70mg+5600rÜ 12tk

Estonia - Estonian - Ravimiamet

mylan pharmaceuticals limited - lamivudiin+abakaviir - õhukese polümeerikattega tablett - 300mg+600mg 60tk; 300mg+600mg 90tk; 300mg+600mg 30tk

Estonia - Estonian - Ravimiamet

mylan ireland limited - posakonasool - suukaudne suspensioon - 40mg 1ml 105ml 1tk

Estonia - Estonian - Ravimiamet

mylan pharmaceuticals limited - agomelatiin - õhukese polümeerikattega tablett - 25mg 98tk; 25mg 28tk; 25mg 56tk; 25mg 42tk; 25mg 100tk

Estonia - Estonian - Ravimiamet

mylan s.a.s. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 5ml 1viaal; 2mg 1ml 100ml 1viaal; 2mg 1ml 10ml 1viaal; 2mg 1ml 25ml 1viaal

Estonia - Estonian - Ravimiamet

mylan s.a.s. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 1000mg 1tk